The multi-targeted tyrosine kinase inhibitor SKLB610 resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs

• Published in: Biomedicine & pharmacotherapy 2022-05, Vol.149, p.112922-112922, Article 112922
• Main Authors: Wu, Chung-Pu, Murakami, Megumi, Wu, Yu-Shan, Lin, Chun-Ling, Li, Yan-Qing, Huang, Yang-Hui, Hung, Tai-Ho, Ambudkar, Suresh V.
• Format: Article
• Language: English
• Subjects: ABCG2; Drug repurposing; Multidrug resistance; SKLB610; VEGFR
• ISSN: 0753-3322; 1950-6007
• DOI: 10.1016/j.biopha.2022.112922

The overexpression of ATP-binding cassette (ABC) transporter ABCB1 (P-glycoprotein) or ABCG2 (BCRP/MXR/ABCP) in cancer cells is frequently associated with the development of multidrug resistance (MDR) in cancer patients, which remains a major obstacle to effective cancer treatment. By utilizing energy derived from ATP hydrolysis, both transporters have been shown to reduce the chemosensitivity of cancer cells by actively effluxing cytotoxic anticancer drugs out of cancer cells. Knowing that there are presently no approved drugs or other therapeutics for the treatment of multidrug-resistant cancers, in recent years, studies have investigated the repurposing of tyrosine kinase inhibitors (TKIs) to act as agents against MDR mediated by ABCB1 and/or ABCG2. SKLB610 is a multi-targeted TKI with potent activity against vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor 2 (FGFR2). In this study, we investigate the interaction of SKLB610 with ABCB1 and ABCG2. We discovered that neither ABCB1 nor ABCG2 confers resistance to SKLB610, but SKLB610 selectively sensitizes ABCG2-overexpressing multidrug-resistant cancer cells to cytotoxic anticancer agents in a concentration-dependent manner. Our data indicate that SKLB610 reverses ABCG2-mediated MDR by attenuating the drug-efflux function of ABCG2 without affecting its total cell expression. These findings are further supported by results of SKLB610-stimulated ABCG2 ATPase activity and in silico docking of SKLB610 in the drug-binding pocket of ABCG2. In summary, we reveal the potential of SKLB610 to overcome resistance to cytotoxic anticancer drugs, which offers an additional treatment option for patients with multidrug-resistant cancers and warrants further investigation. [Display omitted] •ABCG2 overexpression is often associated with multidrug resistance in cancer cells.•SKLB610 selectively reverses multidrug resistance mediated by ABCG2.•SKLB610 attenuates the drug-efflux function of ABCG2.•SKLB610 does not alter the protein expression of ABCG2.•ABCG2 does not confer resistance to SKLB610 in cancer cells.